AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Centrosomal protein of 120 kDa

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8N960

UPID:

CE120_HUMAN

Alternative names:

Coiled-coil domain-containing protein 100

Alternative UPACC:

Q8N960; Q6AI52; Q6AW89; Q8IWB5; Q8N9Y0; Q8NDE8

Background:

Centrosomal protein of 120 kDa, also known as Coiled-coil domain-containing protein 100, is pivotal in microtubule-dependent nucleus-centrosome coupling. It plays a crucial role in centrosome-mediated interkinetic nuclear migration of neural progenitors, neuron positioning during brain development, centriole duplication, maturation during mitosis, and ciliogenesis. Its involvement in neural progenitor migration and self-renewal underscores its significance in cellular dynamics.

Therapeutic significance:

Given its critical role in brain development and association with Short-rib thoracic dysplasia 13 and Joubert syndrome 31, understanding the functions of Centrosomal protein of 120 kDa could unveil novel therapeutic avenues. Targeting the pathways regulated by this protein may offer strategies to mitigate the developmental and skeletal anomalies associated with these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.